88 related articles for article (PubMed ID: 17159912)
1. Cyclooxygenase-2 inhibition promotes enhancement of antitumor responses by transcutaneous vaccination with cytosine-phosphate-guanosine-oligodeoxynucleotides and model tumor antigen.
Inoue J; Aramaki Y
J Invest Dermatol; 2007 Mar; 127(3):614-21. PubMed ID: 17159912
[TBL] [Abstract][Full Text] [Related]
2. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in mice.
Inoue J; Yotsumoto S; Sakamoto T; Tsuchiya S; Aramaki Y
J Control Release; 2005 Nov; 108(2-3):294-305. PubMed ID: 16209897
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor-9 expression induced by tape-stripping triggers on effective immune response with CpG-oligodeoxynucleotides.
Inoue J; Aramaki Y
Vaccine; 2007 Jan; 25(6):1007-13. PubMed ID: 17049678
[TBL] [Abstract][Full Text] [Related]
4. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA-4 blockade.
Davila E; Kennedy R; Celis E
Cancer Res; 2003 Jun; 63(12):3281-8. PubMed ID: 12810660
[TBL] [Abstract][Full Text] [Related]
5. Changes in immune responses to antigen applied to tape-stripped skin with CpG-oligodeoxynucleotide in NC/Nga mice.
Inoue J; Yotsumoto S; Sakamoto T; Tsuchiya S; Aramaki Y
Pharm Res; 2005 Oct; 22(10):1627-33. PubMed ID: 16180119
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with metastasis-related tumor associated antigen TPD52 and CpG/ODN induces protective tumor immunity.
Payton LA; Lewis JD; Byrne JA; Bright RK
Cancer Immunol Immunother; 2008 Jun; 57(6):799-811. PubMed ID: 17962942
[TBL] [Abstract][Full Text] [Related]
7. Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL.
Klimuk SK; Najar HM; Semple SC; Aslanian S; Dutz JP
J Invest Dermatol; 2004 Apr; 122(4):1042-9. PubMed ID: 15102096
[TBL] [Abstract][Full Text] [Related]
8. CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice.
Saha A; Baral RN; Chatterjee SK; Mohanty K; Pal S; Foon KA; Primus FJ; Krieg AM; Weiner GJ; Bhattacharya-Chatterjee M
Cancer Immunol Immunother; 2006 May; 55(5):515-27. PubMed ID: 16044253
[TBL] [Abstract][Full Text] [Related]
9. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
[TBL] [Abstract][Full Text] [Related]
10. CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice.
Switaj T; Jalili A; Jakubowska AB; Drela N; Stoksik M; Nowis D; Basak G; Golab J; Wysocki PJ; Mackiewicz A; Sasor A; Socha K; Jakóbisiak M; Lasek W
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4165-75. PubMed ID: 15217954
[TBL] [Abstract][Full Text] [Related]
11. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
12. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive and efficient transdermal delivery of CpG-oligodeoxynucleotide for cancer immunotherapy.
Kigasawa K; Kajimoto K; Nakamura T; Hama S; Kanamura K; Harashima H; Kogure K
J Control Release; 2011 Mar; 150(3):256-65. PubMed ID: 21256903
[TBL] [Abstract][Full Text] [Related]
14. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.
Sharma S; Yang SC; Zhu L; Reckamp K; Gardner B; Baratelli F; Huang M; Batra RK; Dubinett SM
Cancer Res; 2005 Jun; 65(12):5211-20. PubMed ID: 15958566
[TBL] [Abstract][Full Text] [Related]
15. Encapsulation in liposomal nanoparticles enhances the immunostimulatory, adjuvant and anti-tumor activity of subcutaneously administered CpG ODN.
de Jong S; Chikh G; Sekirov L; Raney S; Semple S; Klimuk S; Yuan N; Hope M; Cullis P; Tam Y
Cancer Immunol Immunother; 2007 Aug; 56(8):1251-64. PubMed ID: 17242927
[TBL] [Abstract][Full Text] [Related]
16. Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses.
Maurer T; Pournaras C; Aguilar-Pimentel JA; Thalgott M; Horn T; Heck M; Heit A; Kuebler H; Gschwend JE; Nawroth R
Urol Oncol; 2013 Oct; 31(7):1395-401. PubMed ID: 21982682
[TBL] [Abstract][Full Text] [Related]
17. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination.
Galea-Lauri J; Wells JW; Darling D; Harrison P; Farzaneh F
Cancer Immunol Immunother; 2004 Nov; 53(11):963-77. PubMed ID: 15146294
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses.
Sharma S; Zhu L; Yang SC; Zhang L; Lin J; Hillinger S; Gardner B; Reckamp K; Strieter RM; Huang M; Batra RK; Dubinett SM
J Immunol; 2005 Jul; 175(2):813-9. PubMed ID: 16002678
[TBL] [Abstract][Full Text] [Related]
19. Synergism between CpG-containing oligodeoxynucleotides and IL-2 causes dramatic enhancement of vaccine-elicited CD8+ T cell responses.
Kochenderfer JN; Chien CD; Simpson JL; Gress RE
J Immunol; 2006 Dec; 177(12):8860-73. PubMed ID: 17142789
[TBL] [Abstract][Full Text] [Related]
20. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection.
Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI
Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]